ORACEA Capsules Provide Multiple Benefits Over Doxycycline 100 mg2,3 | ORACEA Capsules | Doxycycline 100 mg |
---|---|---|
Superior GI tolerability compared to 100 mg2 In a head-to-head clinical study, no nausea, diarrhea or vomiting were reported for ORACEA Capsules (vs 17.3%, 4.3% and 4.3% for doxycycline 100 mg) |
Yes | No |
No evidence of bacterial resistance in a 9-month study3 ORACEA Capsules are precisely formulated (30 mg immediate release/10 mg delayed release) to treat the inflammatory lesions associated with rosacea without increasing the risk of antibiotic resistance. |
Yes | No |
No photosensitivity or vaginal candidiasis reported in controlled clinical studies3 |
Yes | No |
In pivotal clinical studies, the most common treatment-related adverse events (>2%) for ORACEA Capsules were nasopharyngitis (4.8%), diarrhea (4.5%), hypertension (3%), sinusitis (2.6%), and aspartate aminotransferase increase (2.2%).
Help your patients see a positive difference

Not actual patients. Individual results may vary. Results are simulated to show average improvement in clinical trials.
IGA (Investigator’s Global Assessment) Scale
-
4 - Severe
Numerous small and/or large papules/pustules, severe erythema
-
3 - Moderate
Several small or large papules/pustules, moderate erythema
-
2 - Mild
Few small papules/pustules, mild
-
1 - Almost Clear
Very few small papules/pustules, very mild erythema present
-
0 - Clear
No inflammatory lesions present, no erythema